Video

Dr. Brannigan on genetic evaluation of the infertile male

Author(s):

Urology Times staff
Current Time 0:00
Duration 1:15
Loaded: 0.00%
Stream Type LIVE
Remaining Time 1:15
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Robert E. Brannigan, MD, vice chair of Clinical Urology, Northwestern University, discusses which men with infertility issues should receive genetic testing.

    Related Videos
    Perry Xu, MD, answers a question during a Zoom video interview
    Perry Xu, MD, on the potential of AI in the endourology space
    Amy E. Krambeck, MD, answers a question during a Zoom video interview
    Amy E. Krambeck, MD, on what’s needed to improve safety, efficacy of HoLEP
    Illustration of prostate | Image Credit: © Judith - stock.adobe.com
    The role of preoperative imaging with HoLEP for BPH
    Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
    Incorporating emerging technologies into HoLEP for BPH
    Amy E. Krambeck, MD, answers a question during a Zoom video interview
    Amy E. Krambeck, MD, on patient selection for HoLEP
    Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
    An expert on why HoLEP is a “platinum standard” procedure
    Amy E. Krambeck, MD, answers a question during a Zoom video interview
    Amy E. Krambeck, MD, reflects on 754 HoLEP procedures performed by her team in 2024
    Paul Sieber, MD, on the future of genetic testing in prostate cancer
    Paul Sieber, MD, on the future of genetic testing in prostate cancer
    Prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
    Expert: PSMA-PET should be considered at lower PSA levels
    Daniel Kwon, MD, answers a question during a Zoom video interview
    Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer
    Related Content
    Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer
    February 25th 2025

    Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

    Hannah Clarke
    Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.
    Key updates from the AUA/ASRM male infertility guideline amendment
    September 23rd 2024

    Key updates from the AUA/ASRM male infertility guideline amendment

    Urology Times staff
    In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
    Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear
    January 22nd 2025

    Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear

    Hannah Clarke
    "[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    3d rendered genetic illustration of human dna under microscope created with generative ai technology | Image Credit: © Picture Studio - stock.adobe.com
    December 24th 2024

    Quiz: CUA guidelines on specimen and timing considerations with genetic testing

    Patrick Campbell
    Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.
    NCCN reaffirms Prolaris’ prognostic value in prostate cancer
    December 18th 2024

    NCCN reaffirms Prolaris’ prognostic value in prostate cancer

    Hannah Clarke
    The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.
    © 2025 MJH Life Sciences

    All rights reserved.